NPM1 (NUCLEOPHOSMIN1) GENE - AML, in Visit Clinic

The NPM1 mutation in acute myeloid leukemia (AML) is a common genetic change that causes nucleophosmin to relocate from the nucleus to the cytoplasm, disrupting normal cell regulation. It appears in roughly 25–35% of adult AML cases and, when not accompanied by high-risk mutations, is associated with better chemotherapy response. Molecular testing identifies it for prognosis, risk stratification, and treatment planning.

NPM1‑mutated AML generally has a better prognosis than other AML subtypes. With modern therapy, complete remission rates are high and 5‑year overall survival is roughly 40–60% overall. Survival is higher (often >50–60%) in younger patients and those without a co‑occurring FLT3‑ITD mutation, and substantially lower in older patients or with adverse additional mutations.

The most common gene mutation in acute myeloid leukemia (AML) is NPM1 mutation. It occurs in about 25–30% of adult AML cases and is particularly frequent in patients with a normal karyotype. NPM1 mutations often coexist with FLT3 mutations (especially FLT3‑ITD), which can affect prognosis. Detection guides risk stratification and targeted therapy selection.

Acute myeloid leukemia (AML) is not caused by a single gene but by various acquired (somatic) mutations that disrupt blood-cell development. Commonly implicated genes include FLT3 and NPM1, with frequent involvement of DNMT3A, IDH1/2, RUNX1, CEBPA, TP53, ASXL1, and KIT. The specific mutated driver varies by patient and influences prognosis and treatment choices.

Acute myeloid leukemia (AML) is not 100% curable. Some patients—especially younger people with favorable genetic features who achieve complete remission and sometimes receive stem cell transplant—can attain long-term remission or cure. Prognosis varies by age, genetic mutations, disease subtype, and treatment response. Relapse is possible, so ongoing monitoring and individualized therapy are important.

Yes — NPM1 mutation is generally considered a favorable prognostic marker in acute myeloid leukemia, particularly with a normal karyotype and absent or low‑allelic‑ratio FLT3‑ITD. It associates with higher remission rates and improved overall survival, influences risk stratification and treatment choices, and can be used for measurable residual disease monitoring. Impact varies with co‑occurring mutations and clinical context.